AbLec™ Platform
DEVELOPMENT
Broad Therapeutic Potential
Our AbLec™ platform holds promise for multiple therapeutic areas including cancer and auto-immune disease
Cancer Immunotherapy
Challenge: Many tumors evade the immune system by exploiting glyco-immune checkpoints.
AbLec™ Approach: Our constructs can be designed to block these inhibitory signals, eliciting and reactivating anti-tumor immune responses.
Potential Impact: Direct anticancer activity by reducing the glyco-immune checkpoint and inducing stimulatory signals. Enhanced efficacy of existing immunotherapies for unresponsive or relapsed cancers.
Autoimmune Diseases
Challenge: Overactive immune responses lead to self-tissue damage.
AbLec™ Approach: Precisely modulate specific immune cell subsets to restore immune balance and reduce auto-immune responses.
Potential Impact: New targeted therapies with potentially fewer side effects than current broad spectrum immunosuppressants.
The Future of Glyco-immune Modulation
As we advance our understanding of the glyco-immune checkpoint, we're not just developing new therapies – we're opening up an entirely new dimension of immunology. The AbLec™ platform represents the beginning of what we believe will be a transformative approach to treating a wide range of diseases.
At Valora Therapeutics, we are committed to pushing the boundaries of science, translating complex glycobiology into practical, powerful therapies that have the potential to significantly improve patient outcomes across multiple disease areas.